InterCure Ltd. (NASDAQ:INCR – Get Free Report) saw a significant increase in short interest in November. As of November 15th, there was short interest totalling 16,200 shares, an increase of 16.5% from the October 31st total of 13,900 shares. Based on an average daily volume of 32,200 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.1% of the company’s stock are short sold.
InterCure Price Performance
INCR traded down $0.02 on Monday, reaching $1.31. The company’s stock had a trading volume of 24,530 shares, compared to its average volume of 53,589. The business’s 50 day moving average is $1.65 and its 200 day moving average is $2.07. InterCure has a 1 year low of $1.17 and a 1 year high of $3.72. The company has a current ratio of 1.78, a quick ratio of 1.15 and a debt-to-equity ratio of 0.15.
Hedge Funds Weigh In On InterCure
A number of hedge funds have recently added to or reduced their stakes in the business. Tidal Investments LLC bought a new position in InterCure during the 1st quarter worth $883,000. AdvisorShares Investments LLC bought a new position in InterCure during the second quarter valued at about $218,000. Jane Street Group LLC bought a new stake in shares of InterCure in the 3rd quarter worth approximately $49,000. Virtu Financial LLC bought a new stake in shares of InterCure during the 3rd quarter worth $43,000. Finally, Renaissance Technologies LLC increased its stake in InterCure by 30.9% in the 2nd quarter. Renaissance Technologies LLC now owns 45,300 shares of the company’s stock worth $91,000 after purchasing an additional 10,700 shares in the last quarter. Institutional investors and hedge funds own 8.34% of the company’s stock.
About InterCure
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Read More
- Five stocks we like better than InterCure
- What is a Special Dividend?
- How to Master Trading Discipline: Overcome Emotional Challenges
- Consumer Discretionary Stocks Explained
- Trump Tax Reforms: 7 Stocks That Could Benefit in 2025
- How is Compound Interest Calculated?
- 3 Stocks Near 52-Week Lows: Why They Could Be Smart Buys Today
Receive News & Ratings for InterCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InterCure and related companies with MarketBeat.com's FREE daily email newsletter.
